TRIB Jul 2024 2.500 call
| Previous Close | 1.5000 |
| Open | 0.4000 |
| Bid | 0.0000 |
| Ask | 1.0500 |
| Strike | 2.50 |
| Expire Date | 2024-07-19 |
| Day's Range | 0.4000 - 1.5000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 16 |
GlobeNewswireTrinity Biotech Attending 84th Scientific Sessions of the American Diabetes Association
DUBLIN, June 10, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, announces that its senior management team plans to attend the 84th Scientific Sessions of the American Diabetes Association in Orlando Florida, taking place on June 21-24, 2024. Management plans to host meetings with key stakeholders and potential partners as it works t
- GlobeNewswire
Trinity Biotech Launches its Continuous Glucose Monitoring Microsite to Showcase its Innovative & Differentiated Technology
DUBLIN, June 03, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the launch of its continuous glucose monitoring (“CGM”) microsite - https://cgm.trinitybiotech.com. This website will be used to provide the Company’s stakeholders with key insights into the Company’s vision for the development of the next generation of its recently acqu
- GlobeNewswire
Trinity Biotech Announces Q1 2024 Financial Results and Reiterates Guidance
-Business performance on track to achieve approximately $20 million of annualized run-rate EBITDASO1 on annualized revenues of approximately $75 million by Q2 2025- -Strong sequential 39% Q/Q growth on Point-of-Care revenues associated with successful rollout and scaling of HIV test production- -Disciplined execution of operational efficiencies led to 3.6 percentage point Q/Q increase in gross margin percentage with further improvements expected through 2024 and into early 2025- DUBLIN, Ireland,
